On the afternoon of April 1, Chen Jinfu, deputy director of the National Medical Insurance Bureau, and Ding Yilei, deputy director of the price recruitment department of the National Medical Insurance Bureau, came to the headquarters of Yangzijiang Pharmaceutical Group to investigate the production situation and supply capacity of the selected varieties of the national collection. Zhou Ying, Director of Jiangsu Provincial Medical Insurance Bureau, Zhu Lifan, Mayor of Taizhou City, Ye Donghua, Sun Hongjian, leaders of Taizhou Pharmaceutical High-tech Zone and Gaogang District participated in the research, accompanied by Xu Jingren, chairman of Yangzijiang Pharmaceutical Group.

In the exhibition hall of the Pharmaceutical Research Institute of the Group, Chen Jinfu and his delegation listened to the overview of the company's development, the direction of product innovation, and the report on research and development investment. Chen Jinfu learned in detail that with the normalization of national collection, Yangzijiang Pharmaceutical actively responded to the call of the state, so far 58 varieties have passed or deemed to pass the consistency evaluation, and 21 varieties have been successfully selected in the first four batches of national centralized drug procurement, benefiting the majority of patients. Chen Jinfu fully affirmed the enterprise's efforts to ensure the supply of collective-harvest products, and encouraged the enterprise to continue to uphold the concept of high-quality development, adhere to the innovation-oriented, and ensure that the people have access to more high-quality and affordable medical services.